Bulletin from the extraordinary general meeting in CELLINK AB (publ)
At the extraordinary general meeting of CELLINK AB (publ), held on 16 July 2020, the following resolution was passed.
- The extraordinary general meeting resolved, in accordance with the board of directors’ proposal, to authorize the board of directors, until the end of the next annual general meeting, at one or several occasions and with or without deviation from the shareholders’ preferential rights, to resolve on new issue of shares of series B. The authorization may be utilized for new issues of shares of series B with provisions regarding contribution in cash corresponding to a dilution of not more than 10 per cent of the registered share capital in the company at the time of the issue resolution. Deviations from shareholders’ preferential rights should only be possible in connection with acquisitions of operations, companies or participations in companies.
Approximately 77.7% per cent of the votes were represented at the extraordinary general meeting.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00 Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138
The information was submitted for publication, through the agency of the contact persons set out above, on 16 July 2020 at 18.15 p.m. (CEST).
CELLINK is a life-science company developing and delivering life-science solutions for cell culturing, with a focus on three application areas, bioprinting, analysis, and liquid handling and bioprocessing. It develops and markets cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with a global reach in more than 55 countries, CELLINK is changing the future of medicine as we know it.
Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.